AMPK Activators/Inhibitors

AMPK (AMP-activated protein kinase) plays a pivotal role in the regulation of cellular energy homeostasis as the principal energy sensor in most eukaryotic cells. In response to stress, AMPK activation switches on catabolic pathways that generate ATP while simultaneously inactivating biosynthetic pathways that consume ATP.

아이소폼 선택적 제품

Cat.No. 제품명 정보 제품 사용 인용 제품 검증
S7306 Dorsomorphin Dihydrochloride Dorsomorphin 2HCl은 무세포 분석에서 Ki가 109 nM인 강력하고 가역적이며 선택적인 AMPK 억제제이며, ZAPK, SYK, PKCθ, PKA 및 JAK3를 포함한 여러 구조적으로 관련된 키나아제에 대한 유의미한 억제 효과를 나타내지 않습니다. 또한 type Ⅰ BMP receptor 활성을 억제합니다. Dorsomorphin은 암세포주에서 Autophagy를 유도합니다.
EMBO Mol Med, 2026, 10.1038/s44321-026-00411-x
iScience, 2026, 29(1):114339
J Ethnopharmacol, 2026, 365:121576
Verified customer review of Dorsomorphin Dihydrochloride
S1208 Doxorubicin (Adriamycin) Hydrochloride Doxorubicin (DOX) HCl은 IC50 2.67 μM으로 인간 Topoisomerase II를 억제하는 항생제입니다. Doxorubicin은 AMPK의 기저 인산화를 감소시킵니다. Doxorubicin은 HIV 감염 환자의 병용 치료에 사용되지만 HBV 재활성화 위험이 높은 것으로 밝혀졌습니다.본 제품은 PBS 용액에 용해될 때 침전될 수 있습니다. 스톡 용액은 순수한 물로 준비하고, 순수한 물이나 식염수로 희석하여 작업 용액을 얻는 것이 좋습니다.Doxorubicin (Adriamycin) Hydrochloride는 신장 질환의 동물 모델을 유도하는 데 사용할 수 있습니다.
American Journal of Physiology-Gastrointestinal and Liver Physiology, May 1, 2025, G594-G609
Translational Oncology, January 2025, 102204
Research Square, February 21, 2024, nan
Verified customer review of Doxorubicin (Adriamycin) Hydrochloride
S1950 Metformin Hydrochloride Metformin Hydrochloride (1,1-Dimethylbiguanide Hydrochloride)는 매우 효과적인 항고혈당제로서, 주로 간의 포도당 신생합성(간에 의한 포도당 생성)을 억제하여 간세포의 고혈당을 감소시킵니다. 또한 단핵구에서 Mitophagy를 촉진하고 JNK/p38 MAPK 경로 및 GADD153을 활성화하여 폐암 세포의 세포 사멸을 유도합니다.
Cell Biosci, 2025, 15(1):156
mBio, 2025, e0063425
Placenta, 2025, 165:50-61
Verified customer review of Metformin Hydrochloride
S8161 ON123300 ON123300은 CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), Fyn에 대해 각각 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM, 11 nM의 IC50 값을 가지는 강력한 다중 표적 키나아제 억제제입니다.
Cell Rep Med, 2025, S2666-3791(25)00231-9
Cell Rep, 2024, 43(7):114446
J Cell Sci, 2021, jcs.258685
S1396 Resveratrol (trans-Resveratrol) Resveratrol (trans-Resveratrol)은 COX(IC50=1.1 μM), Lipoxygenase(IC50=2.7 μM), 키나아제, Sirtuin 및 기타 단백질을 포함한 광범위한 표적을 가지고 있습니다. 이는 항암, 항염증, 혈당 강하 및 기타 유익한 심혈관 효과를 나타냅니다. Resveratrol (trans-Resveratrol)은 Mitophagy/Autophagy 및 Autophagy 관련 Apoptosis related를 유도합니다.
PLoS One, 2026 Mar 16, e0344872
PLoS One, 2026 Mar 16, e0344872
Theranostics, 2026, 16(9):4768-4786
Verified customer review of Resveratrol (trans-Resveratrol)
S7840 Dorsomorphin (Compound C) Dorsomorphin은 무세포 분석에서 109 nM의 Ki를 갖는 강력하고 가역적인 선택적 AMPK 억제제이며, ZAPK, SYK, PKCθ, PKA 및 JAK3를 포함한 구조적으로 유사한 여러 키나아제에 대해서는 유의미한 억제 효과를 나타내지 않습니다. Dorsomorphin은 BMP type I receptors ALK2, ALK3 and ALK6를 선택적으로 억제합니다. Dorsomorphin은 특정 세포 분화를 촉진하고 암세포주의 Autophagy를 유도하는 데 사용됩니다. 세포 실험의 경우, 수용성인 S7306 Dorsomorphin (Compound C) 2HCl 사용을 권장합니다.
Int Immunol, 2026, dxag005
RSC Adv, 2026, 16(21):18745-18756
Discov Oncol, 2026, 17(1):222
Verified customer review of Dorsomorphin (Compound C)
S1802 AICAR (Acadesine) AICAR (Acadesine, NSC105823, AICA Riboside)은 AMPK 활성제로, AMPK 및 AMPK kinase에 대한 AMP의 자극 효과를 모방하는 ZMP의 축적을 유발합니다. 이 화합물은 Mitophagy를 유도합니다. 임상 3상.
Curr Issues Mol Biol, 2026, 48(4)403
Nat Commun, 2025, 16(1):8478
Theranostics, 2025, 15(15):7567-7583
Verified customer review of AICAR (Acadesine)
S2697 A-769662 A-769662는 세포 무함유 분석에서 0.8 μM의 EC50을 가지며 GPPase/FBPase 활성에는 거의 영향을 미치지 않는 강력하고 가역적인 AMPK 활성제입니다.
FEBS J, 2025, 10.1111/febs.70247
Arch Biochem Biophys, 2025, 769:110433
J Clin Invest, 2024, 134(22)e181314
Verified customer review of A-769662
S5958 Metformin (1,1-Dimethylbiguanide) 제2형 당뇨병 치료제로 널리 사용되는 Metformin (1,1-Dimethylbiguanide)은 간세포에서 AMPK를 활성화합니다. Metformin은 단핵구에서 Mitophagy를 촉진합니다. Metformin은 JNK/p38 MAPK 경로와 GADD153을 활성화하여 폐암 세포의 Apoptosis related를 유도합니다.
Signal Transduct Target Ther, 2025, 10(1):271
Theranostics, 2025, 15(17):9029-9046
Int J Biol Sci, 2025, 21(9):4231-4251
S7898 GSK621 GSK621은 특이적이고 강력한 AMPK 활성제입니다.
Front Pharmacol, 2024, 15:1453647
Sci Rep, 2024, 14(1):5205
Nat Commun, 2023, 14(1):2994
Verified customer review of GSK621

AMPK exists as a heterotrimeric protein complex composed of a catalytic α-subunit (α1 or α2) and regulatory β-subunit (β1 or β2) and γ- subunit (γ1, γ2 or γ3). The structure of the α-subunit consists of a conventional Ser/Thr kinase domain at the N-terminal, an auto-inhibitory domain (AID), an extended linker peptide and the α-subunit C-terminal domain (α-CTD). The β-subunit contains a carbohydrate-binding module (CBM), with the β-subunit C-terminal domain (β-CTD) interacting with both the α-CTD and the amino terminus of the γ-subunit, thus forming the core of the complex. The γ-subunit includes four tandem repeats of a sequence motif, termed a CBS repeat (cystathionine β-synthase, CBS1-4), that forms a flattened disk with one repeat in each quadrant to create four potential ligand binding sites in the centre (site 1-4). AMPK activity increases more than 100-fold when the conserved Thr172 residue in the activation loop of the catalytic α-subunit is phosphorylated by upstream AMPK kinases (AMPKK) such as LKB1 requiring the change in AMP or ADP levels, and CaMKKβ (CaMKK2) in response to increases in cell Ca2+. AMP binding to ligand binding site 1 of the γ subunit allosterically activates the AMPK complex by facilitating the phosphorylation of Thr172 in the catalytic α-subunit, whereas binding of AMP or ADP to site 3 modulates the phosphorylation state of Thr172. In addition to allosteric activation by AMP, the effects on phosphorylation and dephosphorylation of Thr172 can also be produced by ADP, which requires N-terminal myristylation of the β-subunit. [1][2]

AMPK is activated by various types of metabolic stress (glucose deprivation, hypoxia, ischemia, metabolic poisons, or muscle contraction), as well as drugs and xenobiotics (metformin, resveratrol, or berberine) through the classical or canonical mechanisms, which involve increases in cellular AMP, ADP or Ca2+. The metformin for the treatment of people with type 2 diabetes indirectly activates AMPK by increasing cellular AMP and ADP, usually by inhibiting mitochondrial ATP synthesis. Additionally, AMPK activated by resveratrol or metformin upregulates genes involved in oxidative metabolism and oxidative stress resistance by regulating transcription factors of the abnormal dauer formation 16 (DAF-16)/forkhead box O (FOXO) family, contributing to its effects on extending healthy lifespan. Some types of cellular stress such as reactive oxygen species (ROS) and DNA damaging agents (etoposide, doxorubicin and ionizing radiation) activate AMPK by non-canonical mechanisms that involve ATM rather than the increases in AMP, ADP or Ca2+ levels. Activation of AMPK enhances both the transcription and translocation of GLUT4, resulting in an increase in insulin-stimulated glucose uptake. In LKB1-knockout but not AMPKα1-knockout mice, the effects of both AICAR and contraction on glucose uptake are lost. In addition, AMPK also stimulates other catabolic processes such as fatty acid oxidation and glycolysis via inhibition of ACC2 and activation of PFKFB. AMPK is also involved in the regulation of mitochondrial biogenesis through the activation of PGC1α, and the turnover of mitochondria via the special form of autophagy termed mitophagy by activating ULK1, and subsequently triggering autophagy. In addition, mTOR complex-1 (TORC1) can be inhibited by AMPK mediated phosphorylation of both its upstream regulator, TSC2, and the TORC1 subunit Raptor. Consistent with its role in cellular energy homeostasis, AMPK also conserves ATP by switching off almost all anabolic pathways, including the biosynthesis of lipids, carbohydrates, proteins and ribosomal RNA. Moreover, AMPK also functions beyond metabolism through regulation of the cell cycle and modulation of membrane excitability. As LKB1 is a tumor suppressor and is frequently mutated in spontaneous cancers, AMPK-activating drugs such as metformin or A-769662 significantly protect against the development of cancer. [1][2]